back to conferences

American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

date

April 17-22, 2021

location

Virtual

April 17-22, 2021

Founded in 1948, the AAN now represents more than 36,000 members with a goal of expanding and supporting neuroscience research.

The AAN Annual Meeting conference provides the space to learn about scientific breakthroughs and cutting-edge therapeutics, and take advantage of unique opportunities for professional and personal growth.

Quanterix is a proud continued sponsor of the AAN and will be supporting the event this year with a booth in the virtual exhibit hall.
For more information about this event, please visit the AAN website.

If you would like to speak to a representative about how Simoa ultra-sensitive biomarker technology is empowering researchers in the field of neurology, please email sales@quanterix.com.

Presentation Abstracts featuring Simoa Technology at AAN:

Kuhle, J et al         
Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Are Prognostic of Disability Worsening: A Biosignature That Helps Differentiating Active From Non-active SPMS

Ignacio, IG et al   
A Comparative Study of Plasma t-tau and Neurofilament Light Chain in Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Buchmann, A et al              
Serum Neurofilament Light Levels Correlate with Reduced Gray Matter Volume in Advanced Multiple Sclerosis

Polydefkis, M et al              
Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary Transthyretin-Mediated Amyloidosis: Data from the Patisiran Global OLE Study

Dalla Costa, G et al             
Serum neurofilaments predict recovery after acute optic neuritis

Pouzol, L et al      
ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and pro-myelinating effects, for the treatment of inflammatory demyelinating diseases

Kuhle, J et al         
Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 Multiple Sclerosis (MS) Within 2 Years of a First Clinical Demyelinating Event in Patients with MS

Cutter, G et al      
Serum neurofilament light-chain (sNfL) levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis (RRMS) patients in the CombiRx trial

Kuhle, J et al         
Investigating the Correlation Between Serum Neurofilament Light Chain (sNfL) Concentration and Magnetic Resonance Imaging (MRI)-Outcomes in Patients With a First Clinical Demyelinating Event in the REFLEX Trial

Fox, R et al           
Efficacy and safety of the selective oral DHODH modulator vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (EMPhASIS): a randomized, placebo-controlled phase 2 trial

Ziemssen, T et al 
Prognostic Value of Serum NfL for Subclinical Disease Activity and Worsening in Patients with RMS: Results from the Phase 3 ASCLEPIOS I and II Trials

View all AAN Abstracts